Home / Insights
Healthcare AI Procurement Evidence Register: Turning Vendor Claims into Accountable Decisions
Build a healthcare AI procurement evidence register that connects vendor claims to data boundaries, validation evidence, owners and review decisions now.
Healthcare AI Procurement Evidence Register: Turning Vendor Claims into Accountable Decisions Healthcare AI procurement often begins with a confident vendor claim: secure, validated, interoperable, transparent, ready for clinical use, or designed for a particular workflow. Those statements may be useful starting points. They are not yet organisation specific evidence. A healthcare AI procurement evidence register turns a vendor claim into a reviewable decision record. It links a claim to a dated artefact, records what the artefact does and does not demonstrate, assigns a functional owner, captures open questions, and sets a next review. It helps an organisation move from “the vendor told us” to “this is the evidence we considered, this is the decision we made, and this is what must be revisited.” The register is an Eunoia Consulting Co. operating recommendation. It is not a vendor scorecard, legal opinion, clinical determination, compliance certification, or guarantee of safety, fairness, performance, interoperability, or implementation success. A claim is not decision ready evidence A product brochure, a security questionnaire, a validation study, a business associate agreement, an ONC certification statement, or an FDA reference may all be relevant. None should be treated as a universal approval of the local use case. The first job of the register is to separate four categories: 1. Binding requirements that may apply to the organisation and the facts of the use case. 2. Authoritative guidance that can inform risk management but is not automatically binding. 3. Vendor supplied artefacts that require interpretation and local relevance review. 4. Organisation defined operating decisions about use, controls, evidence, and residual risk. For example, HIPAA Security Rule duties apply to covered entities and business associates in scope and address risk analysis and risk management for ePHI. [1] Business associate contract requirements likewise depend on the relationship and the applicable facts. [1] A signed agreement does not prove that a particular AI deployment is secure, appropriate, or compliant. NIST’s AI RMF is voluntary guidance. Its GOVERN, MAP, MEASURE, and MANAGE functions are useful for structuring evidence and review, but they are not a safe harbour or certification. [2] ONC’s decision support intervention certification criterion has a defined Health IT Certification Program scope; it should not be presented as an endorsement of every healthcare AI product. [3] FDA transparency principles and lifecycle materials have their own device specific context. [4] [5] Begin with intended use and the decision boundary The first fields in an evidence register should establish what the organisation is actually deciding. Capture the stated intended use, intended users, target population, care or operating setting, output type, decision role, and the human reviewer or override point. Record what the tool is not approved to do as clearly as what it is intended to support. This is more than documentation. A system described as “AI for healthcare operations” could be used for internal drafting, workflow routing, patient communication, scheduling, documentation, clinical decision support, or financial prioritisation. Each use has different users, data, consequences, and evidence needs. A practical record might ask: What decision or workflow can this output influence? Who is permitted to use it and who is accountable for review? Which populations, sites, or services are in scope? What uses are prohibited, deferred, or subject to separate assessment? What would trigger reassessment of the intended use statement? For healthcare leaders in New York, San Francisco, and San Jose, a shared enterprise register can establish consistency while preserving local implementation facts such as data sources, workflow configuration, user roles, and integration dependencies. Map data boundaries before comparing features A feature comparison can conceal a more consequential question: what information enters, leaves, and persists in the system? The register should identify each material input and output, whether ePHI or PHI may be involved, the stated purpose, retention and deletion terms, training or product improvement position, access roles, hosting or data location statements, subprocessors, integrations, and evidence source. The aim is not to label every vendor relationship the same way. It is to give privacy, security, legal, data governance, and operations reviewers a shared factual map. If a claim is based on a vendor document, record the version and date. If the organisation needs a contractual interpretation, route that question to qualified counsel rather than allowing the register to imply a conclusion. HHS provides Security Rule guidance and explains the roles of covered entities and business associates. [1] Use these materials to identify questions that may be relevant when the legal scope applies. Do not use them to state that every AI supplier is a business associate or that a data location, encryption statement, or agreement alone resolves the organisation’s obligations. Turn validation claims into comparable evidence Healthcare AI buyers often receive performance claims that are difficult to compare. The register should not reproduce the headline alone. For each claim, record the artefact that supports it, the model or product version, date, data set or setting, intended population, evaluation method, reported limitation, and reviewer’s view of local relevance. A vendor study can be valuable while still being incomplete for the organisation’s context. It may address a different workflow, population, implementation configuration, human review process, or data source. The register should make that gap explicit rather than treating a general claim as a local result. Useful evidence fields include: Study, report, test, or release note identifier and date. Product, feature, model, and configuration version. Intended population, setting, and task represented by the evidence. Reported performance and uncertainty, with definitions and limitations. Data quality, subgroup, or fairness information where supplied and relevant. Known failure modes, exclusions, and local dependencies. The decision the evidence supports and the evidence still required. FDA’s transparency principles for machine learning enabled medical devices can inform the question of what stakeholders need to understand about intended use, performance, limitations, data, and changes. [4] These principles apply in a medical device context; they are not a universal certification standard for all healthcare AI. Record implementation dependencies before an approval is final An AI tool may be technically capable but operationally unsuitable until its dependencies are understood. The register should capture interfaces, data mappings, configuration choices, EHR or practice management dependencies, access roles, human review steps, training requirements, logging, monitoring, incident escalation, downtime procedures, and exit or decommissioning needs. This shifts procurement from an isolated buying event to a deployment decision. It also gives operations leaders a clear place to identify implementation work that must be complete before the product moves from evaluation to production. For example, a vendor may describe a capability as automated. The register can ask: What is the human review step? What happens if the connected data feed fails? Who can disable the capability? What data or records must be reconciled? Which staff receive training? Which local policy needs to change? These questions do not assume that automation is unsuitable. They make its operating conditions visible. Make approval and uncertainty visible A register is most useful when it records what remains unresolved. Include the accountable executive, clinical owner where relevant, privacy lead, security lead, procurement or vendor management lead, technical owner, and any other function needed for the decision. Record whether each item is approved, approved with conditions, deferred, rejected, or escalated. For each open issue, capture the requested artefact or action, owner, due date, and the consequence if it is not resolved. The decision record should explain the rationale and any accepted residual risk. This supports accountable governance without forcing every question into a binary yes or no result. The recommended roles and fields are not universal legal requirements. They are a practical way to ensure that the people who own clinical, operational, data, privacy, security, and commercial consequences can see the same evidence before an implementation decision is final. Keep the record current after procurement Evidence expires when the context changes. Record a version, last review date, next review date, and event triggers. Common triggers include a model or feature change, altered data source, new integration, expanded user group, incident, material user feedback, new external evidence, contract renewal, changed certification status, or planned decommissioning. This is where a procurement register becomes a governance asset rather than a folder created for one selection process. NIST’s voluntary framework supports lifecycle risk management and monitoring, while the organisation decides how to apply that approach proportionately. [2] A review can remain concise. The key is that a change returns to a named owner with the current evidence, rather than restarting the discussion from scratch or relying on an outdated vendor representation. A practical starter template A first evidence register can be a table, database record, or controlled working document. It should contain, at minimum: Intended use, decision role, approved users, setting, and out of scope uses. Product, feature, model or configuration version, vendor, and current contract reference. Data inputs and outputs, access, retention, reuse, hosting, subprocessors, and integrations. Evidence link, source, date, reviewer, local applicability, limitations, and decision supported. Implementation dependencies, human review, training, monitoring, incident, fallback, and exit considerations. Accountable owners, approval status, rationale, open questions, requested action, due date, and next review. The register should make a reader able to answer four questions quickly: What are we using? What evidence supports that use? Who decided? What still needs review? Eunoia Consulting Co. works with healthcare organisations to establish practical AI procurement, evidence, and governance workflows that connect vendor diligence to operational reality. To discuss a focused Healthcare AI Procurement Evidence Register for one planned workflow, book a strategy conversation or explore AI governance advisory. This is advisory support for internal decision readiness, not legal, clinical, privacy, security, or regulatory advice. This article was produced by the Eunoia Consulting Co. Editorial Team. Eunoia Consulting Co. specialises in AI governance, healthcare operations, and data strategy for healthcare and veterinary organisations. Sources [1] 45 CFR Part 164 — HIPAA Privacy and Security Rules [2] NIST — AI Risk Management Framework [3] ONC — Decision Support Interventions Certification Criterion [4] FDA — Transparency for Machine Learning Enabled Medical Devices: Guiding Principles [5] FDA — Artificial Intelligence Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations